Clinical Trial Update: Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

View source ↗

Summary

Clinical trial update from University Health Network, Toronto evaluating the risk of myelodysplastic syndrome and acute myeloid leukemia in neuroendocrine tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Status: RECRUITING